Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

Immunogenicity of a recombinant fusion construct composed of intrinsically unstructured, low polymorphic segments derived from merozoite surface protein 2 and trophozoite exported protein 1.

Tiendrebeogo RW, Spallek R, Oehlmann W, Singh M, Theisen M, Nebie I, Moret R, Roussilhon C, Corradin G.

Vaccine. 2019 Aug 23;37(36):5332-5340. doi: 10.1016/j.vaccine.2019.07.048. Epub 2019 Jul 26.

PMID:
31358409
2.

Detection of antisense protein (ASP) RNA transcripts in individuals infected with human immunodeficiency virus type 1 (HIV-1).

Mancarella A, Procopio FA, Achsel T, De Crignis E, Foley BT, Corradin G, Bagni C, Pantaleo G, Graziosi C.

J Gen Virol. 2019 May;100(5):863-876. doi: 10.1099/jgv.0.001244. Epub 2019 Mar 21.

PMID:
30896385
3.

The Candidate Blood-stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase 1 Trial in Exposed and Nonexposed Volunteers.

Steiner-Monard V, Kamaka K, Karoui O, Roethlisberger S, Audran R, Daubenberger C, Fayet-Mello A, Erdmann-Voisin A, Felger I, Geiger K, Govender L, Houard S, Huber E, Mayor C, Mkindi C, Portevin D, Rusch S, Schmidlin S, Tiendrebeogo RW, Theisen M, Thierry AC, Vallotton L, Corradin G, Leroy O, Abdulla S, Shekalaghe S, Genton B, Spertini F, Jongo SA.

Clin Infect Dis. 2019 Jan 18;68(3):466-474. doi: 10.1093/cid/ciy514.

PMID:
29945169
4.

A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein.

Tan J, Sack BK, Oyen D, Zenklusen I, Piccoli L, Barbieri S, Foglierini M, Fregni CS, Marcandalli J, Jongo S, Abdulla S, Perez L, Corradin G, Varani L, Sallusto F, Sim BKL, Hoffman SL, Kappe SHI, Daubenberger C, Wilson IA, Lanzavecchia A.

Nat Med. 2018 May;24(4):401-407. doi: 10.1038/nm.4513. Epub 2018 Mar 19.

5.

The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria.

Karch CP, Doll TAPF, Paulillo SM, Nebie I, Lanar DE, Corradin G, Burkhard P.

J Nanobiotechnology. 2017 Sep 6;15(1):62. doi: 10.1186/s12951-017-0295-0.

6.

Natural immune response to Plasmodium vivax alpha-helical coiled coil protein motifs and its association with the risk of P. vivax malaria.

Céspedes N, Li Wai Suen CSN, Koepfli C, França CT, Felger I, Nebie I, Arévalo-Herrera M, Mueller I, Corradin G, Herrera S.

PLoS One. 2017 Jun 26;12(6):e0179863. doi: 10.1371/journal.pone.0179863. eCollection 2017.

7.

Antibody levels against GLURP R2, MSP1 block 2 hybrid and AS202.11 and the risk of malaria in children living in hyperendemic (Burkina Faso) and hypo-endemic (Ghana) areas.

Adu B, Cherif MK, Bosomprah S, Diarra A, Arthur FK, Dickson EK, Corradin G, Cavanagh DR, Theisen M, Sirima SB, Nebie I, Dodoo D.

Malar J. 2016 Feb 27;15:123. doi: 10.1186/s12936-016-1146-4.

8.

Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.

Balam S, Jafarshad A, Servis C, Frank G, Reed S, Pink R, Druilhe P, Spertini F, Corradin G.

Vaccine. 2016 Mar 18;34(13):1566-1574. doi: 10.1016/j.vaccine.2016.02.013. Epub 2016 Feb 11.

PMID:
26874325
9.

Malaria Vaccines: Progressing on a Bumpy Road.

Corradin G, Nebie I.

EBioMedicine. 2014 Oct 23;1(1):6-7. doi: 10.1016/j.ebiom.2014.10.010. eCollection 2014 Nov. No abstract available.

10.

Plasmodium falciparum merozoite surface protein 2: epitope mapping and fine specificity of human antibody response against non-polymorphic domains.

Balam S, Olugbile S, Servis C, Diakité M, D'Alessandro A, Frank G, Moret R, Nebie I, Tanner M, Felger I, Smith T, Kajava AV, Spertini F, Corradin G.

Malar J. 2014 Dec 19;13:510. doi: 10.1186/1475-2875-13-510.

11.

Priming of CD8(+) T Cell Responses to Liver Stage Malaria Parasite Antigens.

Corradin G, Levitskaya J.

Front Immunol. 2014 Nov 5;5:527. doi: 10.3389/fimmu.2014.00527. eCollection 2014. Review.

12.

Plasmodium vivax antigen discovery based on alpha-helical coiled coil protein motif.

Céspedes N, Habel C, Lopez-Perez M, Castellanos A, Kajava AV, Servis C, Felger I, Moret R, Arévalo-Herrera M, Corradin G, Herrera S.

PLoS One. 2014 Jun 24;9(6):e100440. doi: 10.1371/journal.pone.0100440. eCollection 2014.

13.

Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct.

Céspedes N, Jiménez E, Lopez-Perez M, Rubiano K, Felger I, Alonso P, Arévalo-Herrera M, Corradin G, Herrera S.

Vaccine. 2014 May 30;32(26):3179-86. doi: 10.1016/j.vaccine.2014.04.007. Epub 2014 Apr 13.

PMID:
24731811
14.

Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein.

Céspedes N, Arévalo-Herrera M, Felger I, Reed S, Kajava AV, Corradin G, Herrera S.

Vaccine. 2013 Oct 1;31(42):4923-30. doi: 10.1016/j.vaccine.2013.05.082. Epub 2013 Aug 15.

15.

Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides.

Pellaton C, Perrin Y, Boudousquié C, Barbier N, Wassenberg J, Corradin G, Thierry AC, Audran R, Reymond C, Spertini F.

Clin Transl Allergy. 2013 Jun 1;3(1):17. doi: 10.1186/2045-7022-3-17.

16.

CSP--a model for in vivo presentation of Plasmodium berghei sporozoite antigens by hepatocytes.

Balam S, Romero JF, Bongfen SE, Guillaume P, Corradin G.

PLoS One. 2012;7(12):e51875. doi: 10.1371/journal.pone.0051875. Epub 2012 Dec 18.

17.

Cell biological characterization of the malaria vaccine candidate trophozoite exported protein 1.

Kulangara C, Luedin S, Dietz O, Rusch S, Frank G, Mueller D, Moser M, Kajava AV, Corradin G, Beck HP, Felger I.

PLoS One. 2012;7(10):e46112. doi: 10.1371/journal.pone.0046112. Epub 2012 Oct 8.

18.

Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.

Wetter M, Kowarik M, Steffen M, Carranza P, Corradin G, Wacker M.

Glycoconj J. 2013 Jul;30(5):511-22. doi: 10.1007/s10719-012-9451-9. Epub 2012 Oct 6.

PMID:
23053636
19.

Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guérin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice.

Arama C, Assefaw-Redda Y, Rodriguez A, Fernández C, Corradin G, Kaufmann SH, Reece ST, Troye-Blomberg M.

Vaccine. 2012 Jun 8;30(27):4040-5. doi: 10.1016/j.vaccine.2012.04.029. Epub 2012 Apr 19.

20.

Malaria vaccine development using synthetic peptides as a technical platform.

Corradin G, Céspedes N, Verdini A, Kajava AV, Arévalo-Herrera M, Herrera S.

Adv Immunol. 2012;114:107-49. doi: 10.1016/B978-0-12-396548-6.00005-6. Review.

PMID:
22449780
21.

Functional analysis of Plasmodium vivax VIR proteins reveals different subcellular localizations and cytoadherence to the ICAM-1 endothelial receptor.

Bernabeu M, Lopez FJ, Ferrer M, Martin-Jaular L, Razaname A, Corradin G, Maier AG, Del Portillo HA, Fernandez-Becerra C.

Cell Microbiol. 2012 Mar;14(3):386-400. doi: 10.1111/j.1462-5822.2011.01726.x. Epub 2011 Dec 28.

PMID:
22103402
22.

Malaria vaccine candidate: design of a multivalent subunit α-helical coiled coil poly-epitope.

Olugbile S, Villard V, Bertholet S, Jafarshad A, Kulangara C, Roussilhon C, Frank G, Agak GW, Felger I, Nebie I, Konate K, Kajava AV, Schuck P, Druilhe P, Spertini F, Corradin G.

Vaccine. 2011 Sep 16;29(40):7090-9. doi: 10.1016/j.vaccine.2011.06.122. Epub 2011 Jul 29.

23.

Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Arévalo-Herrera M, Soto L, Perlaza BL, Céspedes N, Vera O, Lenis AM, Bonelo A, Corradin G, Herrera S.

Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):35-42. doi: 10.4269/ajtmh.2011.09-0507.

24.

Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.

Arévalo-Herrera M, Vera O, Castellanos A, Céspedes N, Soto L, Corradin G, Herrera S.

Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):21-7. doi: 10.4269/ajtmh.2011.10-0110.

25.

Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.

Herrera S, Fernández OL, Vera O, Cárdenas W, Ramírez O, Palacios R, Chen-Mok M, Corradin G, Arévalo-Herrera M.

Am J Trop Med Hyg. 2011 Feb;84(2 Suppl):12-20. doi: 10.4269/ajtmh.2011.09-0516.

26.

The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host.

Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA, Corradin G, Persson C, Tewari R, Sinnis P.

J Exp Med. 2011 Feb 14;208(2):341-56. doi: 10.1084/jem.20101488. Epub 2011 Jan 24.

27.

Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies.

Stubbs J, Olugbile S, Saidou B, Simpore J, Corradin G, Lanzavecchia A.

Infect Immun. 2011 Mar;79(3):1143-52. doi: 10.1128/IAI.01034-10. Epub 2010 Dec 28.

28.

Long synthetic peptides for the production of vaccines and drugs: a technological platform coming of age.

Corradin G, Kajava AV, Verdini A.

Sci Transl Med. 2010 Sep 22;2(50):50rv3. doi: 10.1126/scitranslmed.3001387. Review.

PMID:
20861510
29.

Acquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC).

Maestre A, Muskus C, Duque V, Agudelo O, Liu P, Takagi A, Ntumngia FB, Adams JH, Sim KL, Hoffman SL, Corradin G, Velez ID, Wang R.

PLoS One. 2010 Jul 15;5(7):e11437. doi: 10.1371/journal.pone.0011437.

30.

Malaria vaccines - The long synthetic peptide approach: Technical and conceptual advancements.

Olugbile S, Habel C, Servis C, Spertini F, Verdini A, Corradin G.

Curr Opin Mol Ther. 2010 Feb;12(1):64-76. Review.

PMID:
20140818
31.

Malaria vaccine: why is it taking so long?

Corradin G, Kajava AV.

Expert Rev Vaccines. 2010 Feb;9(2):111-4. doi: 10.1586/erv.09.154. No abstract available.

PMID:
20109019
32.

The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.

Audran R, Lurati-Ruiz F, Genton B, Blythman HE, Ofori-Anyinam O, Reymond C, Corradin G, Spertini F.

PLoS One. 2009 Oct 2;4(10):e7304. doi: 10.1371/journal.pone.0007304.

33.

Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.

Olugbile S, Kulangara C, Bang G, Bertholet S, Suzarte E, Villard V, Frank G, Audran R, Razaname A, Nebie I, Awobusuyi O, Spertini F, Kajava AV, Felger I, Druilhe P, Corradin G.

Infect Immun. 2009 Dec;77(12):5701-9. doi: 10.1128/IAI.00652-09. Epub 2009 Sep 28.

34.

Malarial hemozoin is a Nalp3 inflammasome activating danger signal.

Dostert C, Guarda G, Romero JF, Menu P, Gross O, Tardivel A, Suva ML, Stehle JC, Kopf M, Stamenkovic I, Corradin G, Tschopp J.

PLoS One. 2009 Aug 4;4(8):e6510. doi: 10.1371/journal.pone.0006510.

35.

Sequence conservation in Plasmodium falciparum alpha-helical coiled coil domains proposed for vaccine development.

Kulangara C, Kajava AV, Corradin G, Felger I.

PLoS One. 2009 May 25;4(5):e5419. doi: 10.1371/journal.pone.0005419.

36.

Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.

Flueck C, Frank G, Smith T, Jafarshad A, Nebie I, Sirima SB, Olugbile S, Alonso P, Tanner M, Druilhe P, Felger I, Corradin G.

Vaccine. 2009 May 5;27(20):2653-61. doi: 10.1016/j.vaccine.2009.02.081. Epub 2009 Mar 6.

PMID:
19428875
37.

The C-terminal domain of Plasmodium falciparum merozoite surface protein 3 self-assembles into alpha-helical coiled coil tetramer.

Gondeau C, Corradin G, Heitz F, Le Peuch C, Balbo A, Schuck P, Kajava AV.

Mol Biochem Parasitol. 2009 Jun;165(2):153-61. doi: 10.1016/j.molbiopara.2009.01.015. Epub 2009 Feb 10.

38.

Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3.

Toure-Balde A, Perlaza BL, Sauzet JP, Ndiaye M, Aribot G, Tall A, Sokhna C, Rogier C, Corradin G, Roussilhon C, Druilhe P.

Infect Immun. 2009 Mar;77(3):1189-96. doi: 10.1128/IAI.00780-07. Epub 2009 Jan 12.

39.

Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge.

Romero JF, Ciabattini A, Guillaume P, Frank G, Ruggiero P, Pettini E, Del Giudice G, Medaglini D, Corradin G.

Vaccine. 2009 Feb 18;27(8):1266-71. doi: 10.1016/j.vaccine.2008.12.010. Epub 2008 Dec 26.

PMID:
19111883
40.

The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.

Bongfen SE, Ntsama PM, Offner S, Smith T, Felger I, Tanner M, Alonso P, Nebie I, Romero JF, Silvie O, Torgler R, Corradin G.

Vaccine. 2009 Jan 7;27(2):328-35. doi: 10.1016/j.vaccine.2008.09.097. Epub 2008 Nov 5.

PMID:
18984024
41.

Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides.

Perlaza BL, Valencia AZ, Zapata C, Castellanos A, Sauzet JP, Blanc C, Cohen J, Arévalo-Herrera M, Corradin G, Herrera S, Druilhe P.

Eur J Immunol. 2008 Sep;38(9):2610-5. doi: 10.1002/eji.200738055.

42.

Oxidative folding of synthetic polypeptides S-protected as tert-butylthio derivatives.

Verdini A, Terenzi S, Brossard V, Roggero M, Corradin G.

J Pept Sci. 2008 Dec;14(12):1271-82. doi: 10.1002/psc.1067.

PMID:
18781562
43.

Processing of the circumsporozoite protein in infected hepatocytes is not dependent on aspartic proteases.

Bongfen SE, Balam S, Torgler R, Romero JF, Corradin G.

Parasite Immunol. 2008 Jun-Jul;30(6-7):375-8. doi: 10.1111/j.1365-3024.2008.01032.x. Epub 2008 Apr 27.

44.

Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya.

Agak GW, Bejon P, Fegan G, Gicheru N, Villard V, Kajava AV, Marsh K, Corradin G.

Vaccine. 2008 Apr 7;26(16):1963-71. doi: 10.1016/j.vaccine.2008.02.020. Epub 2008 Feb 26.

PMID:
18342997
45.
46.

Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?

Nebie I, Tiono AB, Diallo DA, Samandoulougou S, Diarra A, Konate AT, Cuzin-Ouattara N, Theisen M, Corradin G, Cousens S, Ouattara AS, Ilboudo-Sanogo E, Sirima BS.

Trop Med Int Health. 2008 Feb;13(2):229-37. doi: 10.1111/j.1365-3156.2007.01994.x.

47.

Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.

Stirnemann K, Romero JF, Baldi L, Robert B, Cesson V, Besra GS, Zauderer M, Wurm F, Corradin G, Mach JP, Macdonald HR, Donda A.

J Clin Invest. 2008 Mar;118(3):994-1005. doi: 10.1172/JCI33249.

48.

Protein structure based strategies for antigen discovery and vaccine development against malaria and other pathogens.

Corradin G, Villard V, Kajava AV.

Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):259-65. Review.

PMID:
18220946
49.

Sterile protection against malaria is independent of immune responses to the circumsporozoite protein.

Grüner AC, Mauduit M, Tewari R, Romero JF, Depinay N, Kayibanda M, Lallemand E, Chavatte JM, Crisanti A, Sinnis P, Mazier D, Corradin G, Snounou G, Rénia L.

PLoS One. 2007 Dec 26;2(12):e1371.

50.

IL-12p40-independent induction of protective immunity upon multiple Plasmodium berghei irradiated sporozoite immunizations.

Romero JF, Ibrahim GH, Renggli J, Himmelrich H, Graber P, Corradin G.

Parasite Immunol. 2007 Nov;29(11):541-8.

Supplemental Content

Loading ...
Support Center